Johnson & Johnson (JNJ) Q3 FY26 (Tue Oct 13 premarket) — reported sales $25.4B (+5.9% Y/Y) in line; adj EPS $2.59 (-7.5% Y/Y) misses ~$2.66 est; GAAP EPS collapses to $0.09 on one-time talc litigation special charge; Innovative Medicine <meta name="viewport" content="width=device-width, initial-scale=1.0" />6.76B (+7.7%, ex-Stelara +~15%), MedTech $8.64B (+2.5%); FY26 adj EPS guide RAISED to <meta name="viewport" content="width=device-width, initial-scale=1.0" />1.05-<meta name="viewport" content="width=device-width, initial-scale=1.0" />1.15 (prior <meta name="viewport" content="width=device-width, initial-scale=1.0" />0.96-<meta name="viewport" content="width=device-width, initial-scale=1.0" />1.11)

6.76B (+7.7%, ex-Stelara +~15%), MedTech $8.64B (+2.5%); FY26 adj EPS guide RAISED to 1.05-1.15 (prior 0.96-1.11)" /> 6.76B (+7.7%, ex-Stelara +~15%), MedTech $8.64B (+2.5%); FY26 adj EPS guide RAISED to 1.05-1.15 (prior 0.96-1.11)" />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.